Non-Ergot Dopamine Agonists and the Risk of Heart Failure and Other Adverse Cardiovascular Reactions in Parkinson's Disease

Reports suggest possible risks of adverse cardiovascular reactions, including heart failure, associated with non-ergot dopamine agonist (DA) use in Parkinson's disease (PD). The objectives of our review were to evaluate the risk of heart failure and other adverse cardiovascular reactions in PD...

Full description

Saved in:
Bibliographic Details
Published inBrain sciences Vol. 14; no. 8; p. 776
Main Authors Crispo, James A G, Farhat, Nawal, Fortin, Yannick, Perez-Lloret, Santiago, Sikora, Lindsey, Morgan, Rebecca L, Habash, Mara, Gogna, Priyanka, Kelly, Shannon E, Elliott, Jesse, Kohen, Dafna E, Bjerre, Lise M, Mattison, Donald R, Hessian, Renée C, Willis, Allison W, Krewski, Daniel
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 31.07.2024
MDPI
Subjects
Agonists
Bias
Bromocriptine
Canada
Cardiac glycosides
Cardiac patients
Cardiotonic agents
Cardiovascular disease
Cardiovascular diseases
cardiovascular reactions
Clinical trials
Comparative analysis
Complications and side effects
Congestive heart failure
Diseases
Dopamine
Drug dosages
Edema
Enzymes
Ergot
Heart diseases
Heart failure
Intervention
medication safety
Movement disorders
Neurodegenerative diseases
non-ergot dopamine agonists
Online databases
Ontario
Orthostatic hypotension
Parkinson's disease
Phenols
Restless legs syndrome
Risk factors
Ropinirole
Systematic Review
Canada
Ontario
United States > US
heart failure
non-ergot dopamine agonists
medication safety
meta-analysis
non-randomized studies
cardiovascular reactions
randomized controlled trials
systematic review
Parkinson’s disease
Online AccessGet full text

Cover

Abstract Reports suggest possible risks of adverse cardiovascular reactions, including heart failure, associated with non-ergot dopamine agonist (DA) use in Parkinson's disease (PD). The objectives of our review were to evaluate the risk of heart failure and other adverse cardiovascular reactions in PD patients who received a non-ergot DA compared with other anti-PD pharmacological interventions, placebo, or no intervention. Studies were identified via searches of six bibliographic databases. Randomized controlled trials (RCTs) and non-randomized studies (NRS) were eligible for study inclusion. Random-effect meta-analyses were performed to estimate adverse cardiovascular reaction risks. Quality of evidence was assessed using GRADE. In total, forty-four studies (thirty-six RCTs and eight NRS) satisfied our inclusion criteria. A single RCT found no significant difference in the risk of heart failure with ropinirole compared with bromocriptine (odds ratio (OR) 0.39, 95% confidence interval (CI) 0.07 to 2.04; low certainty). Conversely, three case-control studies reported a risk of heart failure with non-ergot DA treatment. The quality of evidence for the risk of heart failure was judged as low or very low. Findings suggest that non-ergot DA use may be associated with adverse cardiovascular outcomes, including heart failure. Studies are needed to better understand cardiovascular risks associated with PD treatment.
AbstractList Reports suggest possible risks of adverse cardiovascular reactions, including heart failure, associated with non-ergot dopamine agonist (DA) use in Parkinson’s disease (PD). The objectives of our review were to evaluate the risk of heart failure and other adverse cardiovascular reactions in PD patients who received a non-ergot DA compared with other anti-PD pharmacological interventions, placebo, or no intervention. Studies were identified via searches of six bibliographic databases. Randomized controlled trials (RCTs) and non-randomized studies (NRS) were eligible for study inclusion. Random-effect meta-analyses were performed to estimate adverse cardiovascular reaction risks. Quality of evidence was assessed using GRADE. In total, forty-four studies (thirty-six RCTs and eight NRS) satisfied our inclusion criteria. A single RCT found no significant difference in the risk of heart failure with ropinirole compared with bromocriptine (odds ratio (OR) 0.39, 95% confidence interval (CI) 0.07 to 2.04; low certainty). Conversely, three case–control studies reported a risk of heart failure with non-ergot DA treatment. The quality of evidence for the risk of heart failure was judged as low or very low. Findings suggest that non-ergot DA use may be associated with adverse cardiovascular outcomes, including heart failure. Studies are needed to better understand cardiovascular risks associated with PD treatment.
Reports suggest possible risks of adverse cardiovascular reactions, including heart failure, associated with non-ergot dopamine agonist (DA) use in Parkinson's disease (PD). The objectives of our review were to evaluate the risk of heart failure and other adverse cardiovascular reactions in PD patients who received a non-ergot DA compared with other anti-PD pharmacological interventions, placebo, or no intervention. Studies were identified via searches of six bibliographic databases. Randomized controlled trials (RCTs) and non-randomized studies (NRS) were eligible for study inclusion. Random-effect meta-analyses were performed to estimate adverse cardiovascular reaction risks. Quality of evidence was assessed using GRADE. In total, forty-four studies (thirty-six RCTs and eight NRS) satisfied our inclusion criteria. A single RCT found no significant difference in the risk of heart failure with ropinirole compared with bromocriptine (odds ratio (OR) 0.39, 95% confidence interval (CI) 0.07 to 2.04; low certainty). Conversely, three case-control studies reported a risk of heart failure with non-ergot DA treatment. The quality of evidence for the risk of heart failure was judged as low or very low. Findings suggest that non-ergot DA use may be associated with adverse cardiovascular outcomes, including heart failure. Studies are needed to better understand cardiovascular risks associated with PD treatment.Reports suggest possible risks of adverse cardiovascular reactions, including heart failure, associated with non-ergot dopamine agonist (DA) use in Parkinson's disease (PD). The objectives of our review were to evaluate the risk of heart failure and other adverse cardiovascular reactions in PD patients who received a non-ergot DA compared with other anti-PD pharmacological interventions, placebo, or no intervention. Studies were identified via searches of six bibliographic databases. Randomized controlled trials (RCTs) and non-randomized studies (NRS) were eligible for study inclusion. Random-effect meta-analyses were performed to estimate adverse cardiovascular reaction risks. Quality of evidence was assessed using GRADE. In total, forty-four studies (thirty-six RCTs and eight NRS) satisfied our inclusion criteria. A single RCT found no significant difference in the risk of heart failure with ropinirole compared with bromocriptine (odds ratio (OR) 0.39, 95% confidence interval (CI) 0.07 to 2.04; low certainty). Conversely, three case-control studies reported a risk of heart failure with non-ergot DA treatment. The quality of evidence for the risk of heart failure was judged as low or very low. Findings suggest that non-ergot DA use may be associated with adverse cardiovascular outcomes, including heart failure. Studies are needed to better understand cardiovascular risks associated with PD treatment.
Audience Academic
Author Morgan, Rebecca L
Bjerre, Lise M
Kohen, Dafna E
Mattison, Donald R
Perez-Lloret, Santiago
Sikora, Lindsey
Kelly, Shannon E
Krewski, Daniel
Hessian, Renée C
Habash, Mara
Elliott, Jesse
Gogna, Priyanka
Farhat, Nawal
Willis, Allison W
Fortin, Yannick
Crispo, James A G
AuthorAffiliation 16 Department of Neurology, Translational Center of Excellence for Neuroepidemiology and Neurological Outcomes Research, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
11 Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, Ottawa, ON K1Y 4W7, Canada
5 Observatorio de Salud, Pontificia Universidad Católica Argentina, Consejo de Investigaciones Científicas y Técnicas (UCA-CONICET), Buenos Aires C1107AAZ, Argentina
12 Department of Family Medicine, University of Ottawa, Ottawa, ON K1G 5Z3, Canada
6 Departamento de Fisiología, Facultad de Medicina, Universidad de Buenos Aires (UBA), Buenos Aires C1121ABG, Argentina
15 University of Ottawa Heart Institute, University of Ottawa, Ottawa, ON K1Y 4W7, Canada
3 Human Sciences Division, NOSM University, Sudbury, ON P3E 2C6, Canada
4 School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON K1G 5Z3, Canada
1 McLaughlin Centre for Population Health Risk Assessment, University
AuthorAffiliation_xml – name: 2 Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
– name: 11 Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, Ottawa, ON K1Y 4W7, Canada
– name: 10 Department of Public Health Sciences, Queen’s University, Kingston, ON K7L 3N6, Canada
– name: 5 Observatorio de Salud, Pontificia Universidad Católica Argentina, Consejo de Investigaciones Científicas y Técnicas (UCA-CONICET), Buenos Aires C1107AAZ, Argentina
– name: 3 Human Sciences Division, NOSM University, Sudbury, ON P3E 2C6, Canada
– name: 4 School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON K1G 5Z3, Canada
– name: 9 Aboriginal Cancer Control Unit, Cancer Care Ontario, Toronto, ON M5G 2L7, Canada
– name: 13 Institut du Savoir Montfort, Ottawa, ON K1K 0T2, Canada
– name: 1 McLaughlin Centre for Population Health Risk Assessment, University of Ottawa, Ottawa, ON K1G 5Z3, Canada
– name: 16 Department of Neurology, Translational Center of Excellence for Neuroepidemiology and Neurological Outcomes Research, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
– name: 14 Risk Sciences International, Ottawa, ON K1P 5J6, Canada
– name: 8 Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON L8S 4L8, Canada
– name: 12 Department of Family Medicine, University of Ottawa, Ottawa, ON K1G 5Z3, Canada
– name: 7 Health Sciences Library, University of Ottawa, Ottawa, ON K1H 8M5, Canada
– name: 15 University of Ottawa Heart Institute, University of Ottawa, Ottawa, ON K1Y 4W7, Canada
– name: 6 Departamento de Fisiología, Facultad de Medicina, Universidad de Buenos Aires (UBA), Buenos Aires C1121ABG, Argentina
Author_xml – sequence: 1
  givenname: James A G
  surname: Crispo
  fullname: Crispo, James A G
  organization: Human Sciences Division, NOSM University, Sudbury, ON P3E 2C6, Canada
– sequence: 2
  givenname: Nawal
  surname: Farhat
  fullname: Farhat, Nawal
  organization: School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON K1G 5Z3, Canada
– sequence: 3
  givenname: Yannick
  surname: Fortin
  fullname: Fortin, Yannick
  organization: McLaughlin Centre for Population Health Risk Assessment, University of Ottawa, Ottawa, ON K1G 5Z3, Canada
– sequence: 4
  givenname: Santiago
  orcidid: 0000-0001-9069-6512
  surname: Perez-Lloret
  fullname: Perez-Lloret, Santiago
  organization: Departamento de Fisiología, Facultad de Medicina, Universidad de Buenos Aires (UBA), Buenos Aires C1121ABG, Argentina
– sequence: 5
  givenname: Lindsey
  orcidid: 0000-0002-9715-8634
  surname: Sikora
  fullname: Sikora, Lindsey
  organization: Health Sciences Library, University of Ottawa, Ottawa, ON K1H 8M5, Canada
– sequence: 6
  givenname: Rebecca L
  surname: Morgan
  fullname: Morgan, Rebecca L
  organization: Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON L8S 4L8, Canada
– sequence: 7
  givenname: Mara
  surname: Habash
  fullname: Habash, Mara
  organization: Aboriginal Cancer Control Unit, Cancer Care Ontario, Toronto, ON M5G 2L7, Canada
– sequence: 8
  givenname: Priyanka
  surname: Gogna
  fullname: Gogna, Priyanka
  organization: Department of Public Health Sciences, Queen's University, Kingston, ON K7L 3N6, Canada
– sequence: 9
  givenname: Shannon E
  surname: Kelly
  fullname: Kelly, Shannon E
  organization: Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, Ottawa, ON K1Y 4W7, Canada
– sequence: 10
  givenname: Jesse
  surname: Elliott
  fullname: Elliott, Jesse
  organization: School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON K1G 5Z3, Canada
– sequence: 11
  givenname: Dafna E
  surname: Kohen
  fullname: Kohen, Dafna E
  organization: School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON K1G 5Z3, Canada
– sequence: 12
  givenname: Lise M
  surname: Bjerre
  fullname: Bjerre, Lise M
  organization: Institut du Savoir Montfort, Ottawa, ON K1K 0T2, Canada
– sequence: 13
  givenname: Donald R
  surname: Mattison
  fullname: Mattison, Donald R
  organization: Risk Sciences International, Ottawa, ON K1P 5J6, Canada
– sequence: 14
  givenname: Renée C
  surname: Hessian
  fullname: Hessian, Renée C
  organization: University of Ottawa Heart Institute, University of Ottawa, Ottawa, ON K1Y 4W7, Canada
– sequence: 15
  givenname: Allison W
  surname: Willis
  fullname: Willis, Allison W
  organization: Department of Neurology, Translational Center of Excellence for Neuroepidemiology and Neurological Outcomes Research, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
– sequence: 16
  givenname: Daniel
  surname: Krewski
  fullname: Krewski, Daniel
  organization: Risk Sciences International, Ottawa, ON K1P 5J6, Canada
BackLink https://www.ncbi.nlm.nih.gov/pubmed/39199470$$D View this record in MEDLINE/PubMed
BookMark eNptks9PFDEUxycGI4jcPZkmHvSy2J8znZPZLCAkRAzRc_OmP5Yus-3azmxi_OftACJLbA9t3vu-T99rvq-rvRCDraq3BB8z1uJPXQIfsvaEY4mbpn5RHVDc1DPGqdh7ct-vjnJe4bIkxkzgV9U-a0nb8gYfVL-_xjA7Tcs4oJO4gbUPFs2XMfg8ZATBoOHGomufb1F06NxCGtAZ-H5M9i57VdIJzc3WpmzRApLxcQtZjz0kdG1BDz6GjHxA3yDdlnZj-JDRic8Wsn1TvXTQZ3v0cB5WP85Ovy_OZ5dXXy4W88uZ5pwMM8FNR4XE0nTYUI6J0EbophZaU2haoqVgGhhrOnCd67TstDPcNm3neAuOsMPq4p5rIqzUJvk1pF8qgld3gZiWqszldW-V6KQQlLWOcsM7riWpa2EYZ9JRUde0sD7fszZjt7ZG2zAk6Hegu5ngb9QybhUhrIDZ1M3HB0KKP0ebB7X2Wdu-h2DjmBXDbUs4pXySvn8mXcUxhfJXk6qRTNYU_1MtoUzgg4vlYT1B1bwYgxcP0Il1_B9V2cauvS7Ocr7EdwrwfYFOMedk3eOQBKvJgOq5AUvJu6ef81jw127sD_Ty2Mc
Cites_doi 10.1002/mds.23204
10.2165/00003495-199346030-00005
10.1097/00002826-199508000-00006
10.1002/mds.20750
10.1212/01.wnl.0000238508.68593.1d
10.1016/j.parkreldis.2008.07.004
10.1016/S1474-4422(13)70117-0
10.1016/S1474-4422(18)30239-4
10.1136/jnnp.63.5.584
10.1212/01.wnl.0000258660.74391.c1
10.1007/s00228-011-1084-6
10.1016/j.parkreldis.2014.10.005
10.1016/j.parkreldis.2012.01.012
10.1097/MNH.0b013e32831a9e0b
10.1517/14740338.2014.888057
10.1136/bmj.39500.677199.AE
10.1136/jnnp.2003.020982
10.1152/ajprenal.00583.2011
10.1016/j.jocn.2013.10.041
10.1002/mds.22036
10.1002/mds.10359
10.1007/s004150070075
10.1001/archneur.60.12.1721
10.1016/S1474-4422(07)70218-1
10.1161/01.HYP.19.6.508
10.1016/j.jclinepi.2010.09.011
10.1002/mdc3.12286
10.1007/s00702-008-0179-4
10.1017/S031716710001516X
10.2165/00002018-199819010-00002
10.1007/s40266-013-0102-z
10.1007/s10286-007-1001-3
10.1001/archneur.57.10.1461
10.1007/s40263-013-0053-2
10.1056/NEJM199810083391506
10.1212/WNL.0b013e31822affdb
10.4065/77.12.1280
10.1111/j.1468-1331.2008.02214.x
10.1002/pds.2267
10.1002/mds.870130111
10.1212/01.wnl.0000265593.34438.00
10.2165/11319860-000000000-00000
10.1097/MD.0000000000011316
10.1016/j.phrs.2011.11.009
10.1002/mds.21639
10.1016/S1474-4422(09)70225-X
10.1097/WNF.0b013e31825f77b9
10.1212/WNL.49.4.1060
10.1002/mds.23590
10.1002/mds.21225
10.2217/nmt-2016-0038
10.1212/01.wnl.0000252355.79284.22
10.2165/11537810-000000000-00000
10.1093/gerona/56.12.M749
10.1017/S0317167100008593
10.1186/2047-9158-3-11
10.1007/s00415-003-0937-z
10.1212/WNL.49.1.162
10.1185/03007995.2012.752351
10.1002/mds.10538
10.1007/s40266-013-0090-z
10.1111/j.1472-8206.2012.01028.x
10.1139/y02-081
10.1161/01.HYP.0000188052.69549.e4
10.1007/s00702-012-0946-0
10.1002/mds.23498
10.1016/j.parkreldis.2013.07.009
10.1056/NEJM200005183422004
10.1016/j.parkreldis.2011.04.016
10.1046/j.1468-1331.1998.530235.x
10.1016/S0163-7258(99)00029-7
10.1042/CS20070018
10.1159/000275491
10.1002/mds.23396
10.1080/09540260802095123
10.1007/s40263-015-0293-4
10.1016/B978-0-12-394623-2.00015-9
10.1016/S1474-4422(07)70108-4
10.4103/0974-1208.121400
10.1016/S1353-8020(09)70835-1
10.1002/mds.21122
10.1016/S1474-4422(10)70106-X
10.1212/01.wnl.0000259516.61938.bb
10.1016/S1353-8020(11)70026-8
10.1002/mds.20887
10.1002/mds.20397
10.1212/WNL.53.2.364
10.1097/00002826-199619030-00005
10.1111/j.1365-2710.2005.00629.x
10.1016/S0140-6736(09)60252-X
ContentType Journal Article
Copyright COPYRIGHT 2024 MDPI AG
2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2024 by the authors. 2024
Copyright_xml – notice: COPYRIGHT 2024 MDPI AG
– notice: 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2024 by the authors. 2024
DBID NPM
AAYXX
CITATION
3V.
7TK
7XB
8FE
8FH
8FK
8G5
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
GNUQQ
GUQSH
HCIFZ
LK8
M2O
M7P
MBDVC
PIMPY
PQEST
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
DOA
DOI 10.3390/brainsci14080776
DatabaseName PubMed
CrossRef
ProQuest Central (Corporate)
Neurosciences Abstracts
ProQuest Central (purchase pre-March 2016)
ProQuest SciTech Collection
ProQuest Natural Science Collection
ProQuest Central (Alumni) (purchase pre-March 2016)
Research Library (Alumni Edition)
ProQuest Central (Alumni)
ProQuest Central
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central Korea
ProQuest Central Student
Research Library Prep
SciTech Premium Collection
Biological Sciences
Research Library
Biological Science Database
Research Library (Corporate)
Publicly Available Content (ProQuest)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
Directory of Open Access Journals
DatabaseTitle PubMed
CrossRef
Publicly Available Content Database
Research Library Prep
ProQuest Central Student
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
Research Library (Alumni Edition)
ProQuest Natural Science Collection
Biological Science Database
ProQuest SciTech Collection
Neurosciences Abstracts
ProQuest Central China
ProQuest Central
ProQuest One Academic UKI Edition
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
ProQuest Research Library
ProQuest One Academic
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList CrossRef

MEDLINE - Academic

PubMed

Publicly Available Content Database
Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: AUTh Library subscriptions: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Anatomy & Physiology
EISSN 2076-3425
ExternalDocumentID oai_doaj_org_article_5b855239f24d4b4c81665d3438f25662
A807434221
10_3390_brainsci14080776
39199470
Genre Journal Article
Review
GeographicLocations Canada
Ontario
United States--US
GeographicLocations_xml – name: Ontario
– name: Canada
– name: United States--US
GrantInformation_xml – fundername: McLaughlin Centre for Population Health Risk Assessment at the University of Ottawa
  grantid: n/a
– fundername: Natural Sciences and Engineering Council of Canada Research Chair in Risk Science (2015–2020)
– fundername: Ministry of Science, Technology and Productive Innovation (MINCyT) in Argentina
– fundername: Fulbright Canada (2014–2015)
– fundername: Ontario Graduate Scholarship Program (2012–2013)
– fundername: McLaughlin Centre for Population Health Risk Assessment at the University of Ottawa
– fundername: Canadian Institutes of Health Research (Doctoral Research Award—Priority Announcement: Drug Safety and Effectiveness (2013–2016))
– fundername: University of Ottawa (Ottawa, Canada)
GroupedDBID 3V.
53G
5VS
8FE
8FH
8G5
AADQD
AAFWJ
ABDBF
ABUWG
ADBBV
AFKRA
AFZYC
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
CCPQU
DWQXO
EBD
ESX
GNUQQ
GROUPED_DOAJ
GUQSH
HCIFZ
HYE
IAO
IHR
ITC
KQ8
LK8
M2O
M48
M7P
MODMG
M~E
NPM
OK1
PGMZT
PIMPY
PQQKQ
PROAC
RPM
AAYXX
CITATION
7TK
7XB
8FK
MBDVC
PQEST
PQUKI
PRINS
Q9U
7X8
5PM
AFPKN
ID FETCH-LOGICAL-c441t-54db25808db0d24015cd5c765cc2a791c853ca337bafbfbc8bcfd4e79bf49af13
IEDL.DBID RPM
ISSN 2076-3425
IngestDate Tue Oct 22 15:16:21 EDT 2024
Thu Aug 29 07:30:57 EDT 2024
Sat Oct 26 04:07:50 EDT 2024
Thu Oct 10 22:00:24 EDT 2024
Tue Nov 19 21:29:59 EST 2024
Tue Nov 12 23:35:35 EST 2024
Fri Dec 06 08:53:59 EST 2024
Sat Nov 02 12:25:20 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 8
Keywords heart failure
non-ergot dopamine agonists
medication safety
meta-analysis
non-randomized studies
cardiovascular reactions
randomized controlled trials
systematic review
Parkinson’s disease
Language English
License https://creativecommons.org/licenses/by/4.0
Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c441t-54db25808db0d24015cd5c765cc2a791c853ca337bafbfbc8bcfd4e79bf49af13
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
These authors contributed equally to this work.
ORCID 0000-0002-9715-8634
0000-0001-9069-6512
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11352331/
PMID 39199470
PQID 3097838620
PQPubID 2032423
ParticipantIDs doaj_primary_oai_doaj_org_article_5b855239f24d4b4c81665d3438f25662
pubmedcentral_primary_oai_pubmedcentral_nih_gov_11352331
proquest_miscellaneous_3099142241
proquest_journals_3097838620
gale_infotracmisc_A807434221
gale_infotracacademiconefile_A807434221
crossref_primary_10_3390_brainsci14080776
pubmed_primary_39199470
PublicationCentury 2000
PublicationDate 20240731
PublicationDateYYYYMMDD 2024-07-31
PublicationDate_xml – month: 7
  year: 2024
  text: 20240731
  day: 31
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
– name: Basel
PublicationTitle Brain sciences
PublicationTitleAlternate Brain Sci
PublicationYear 2024
Publisher MDPI AG
MDPI
Publisher_xml – name: MDPI AG
– name: MDPI
References LeWitt (ref_52) 2007; 68
Mokhles (ref_24) 2012; 65
Zeng (ref_92) 2007; 112
Simonis (ref_107) 2007; 22
Watts (ref_69) 2007; 68
Montastruc (ref_93) 1993; 46
Rutan (ref_83) 1992; 19
Stowe (ref_104) 2008; 2008
Sprenger (ref_11) 2013; 27
Velseboer (ref_80) 2011; 17
Barone (ref_45) 2010; 9
Emilien (ref_90) 1999; 84
Rey (ref_95) 2013; 27
Bonuccelli (ref_12) 2009; 15
Kieburtz (ref_51) 2011; 26
Senard (ref_79) 1997; 63
Katsuki (ref_15) 2012; 89
Rousseau (ref_91) 2002; 80
Vilas (ref_19) 2012; 18
Im (ref_35) 2003; 250
Delwaide (ref_47) 2006; 21
Hubble (ref_37) 1995; 18
Evanoff (ref_5) 2010; 34
Baker (ref_100) 2009; 15
Rey (ref_84) 2012; 18
ref_29
ref_28
ref_27
ref_26
Seiple (ref_65) 2016; 2016
Wooten (ref_4) 2004; 75
Lieberman (ref_38) 1997; 49
Tran (ref_99) 2015; 29
Nicholas (ref_57) 2014; 4
Crispo (ref_34) 2016; 3
Peralta (ref_25) 2006; 21
Mizuno (ref_53) 2012; 35
Rascol (ref_60) 2000; 342
Heinonen (ref_89) 1998; 19
Majumdar (ref_13) 2013; 6
Rascol (ref_39) 1998; 13
Clarke (ref_101) 2000; 2000
Viallet (ref_67) 2013; 29
Merims (ref_8) 2008; 20
Lieberman (ref_9) 2013; 120
Grosset (ref_48) 2013; 3
Junghanns (ref_20) 2007; 22
Poewe (ref_59) 2007; 6
Rascol (ref_40) 1996; 19
Low (ref_81) 2008; 18
Lang (ref_1) 1998; 339
Casey (ref_6) 2013; 19
Zhang (ref_71) 2013; 19
Clarke (ref_102) 2001; 2001
Yang (ref_78) 2012; 302
Katzenschlager (ref_50) 2018; 17
Haapaniemi (ref_85) 2000; 247
Pritchett (ref_97) 2002; 77
Antonini (ref_73) 2009; 8
Schapira (ref_64) 2013; 12
Steiger (ref_22) 2009; 116
Goldstein (ref_88) 2005; 46
Zhou (ref_105) 2014; 21
Biglan (ref_96) 2007; 69
Guttman (ref_36) 1997; 49
Poon (ref_82) 2005; 30
Stocchi (ref_66) 2011; 26
Rey (ref_10) 2014; 13
Sampaio (ref_62) 2011; 26
Nirenberg (ref_14) 2013; 30
Arbouw (ref_75) 2012; 68
Mizuno (ref_54) 2014; 20
Hsieh (ref_76) 2013; 30
Kulisevsky (ref_103) 2010; 33
Giladi (ref_108) 2016; 6
Yamamoto (ref_42) 2006; 67
Shen (ref_106) 2018; 97
Radad (ref_17) 2005; 57
Ziegler (ref_72) 2003; 18
Schapira (ref_63) 2011; 77
Wang (ref_68) 2014; 3
Gildea (ref_77) 2009; 18
Bhattacharyya (ref_98) 2009; 374
Grimes (ref_7) 2012; 39
Guyatt (ref_31) 2011; 64
Renoux (ref_21) 2012; 21
Wermuth (ref_41) 1998; 5
Rascol (ref_61) 2006; 21
Pahwa (ref_58) 2007; 68
Zesiewicz (ref_70) 2017; 7
Titlic (ref_44) 2008; 109
ref_30
Schunemann (ref_32) 2008; 336
Moller (ref_55) 2005; 20
Holloway (ref_49) 2004; 61
Blindeauer (ref_46) 2003; 60
Navan (ref_56) 2003; 18
Muangpaisan (ref_2) 2011; 94
Antonini (ref_74) 2007; 6
Rascol (ref_18) 2010; 24
Boerman (ref_87) 2001; 56
ref_3
Yamashiro (ref_43) 2008; 23
Moller (ref_16) 2008; 15
Zadikoff (ref_23) 2008; 35
Rascol (ref_94) 2010; 25
Korczyn (ref_33) 1999; 53
Kujawa (ref_86) 2000; 57
References_xml – volume: 19
  start-page: 20
  year: 2013
  ident: ref_6
  article-title: Parkinson’s disease: A long and difficult journey
  publication-title: Nurs. N. Z.
  contributor:
    fullname: Casey
– volume: 25
  start-page: 1876
  year: 2010
  ident: ref_94
  article-title: Adverse drug reactions to dopamine agonists: A comparative study in the french pharmacovigilance database
  publication-title: Mov. Disord.
  doi: 10.1002/mds.23204
  contributor:
    fullname: Rascol
– volume: 46
  start-page: 384
  year: 1993
  ident: ref_93
  article-title: Current status of dopamine agonists in Parkinson’s disease management
  publication-title: Drugs
  doi: 10.2165/00003495-199346030-00005
  contributor:
    fullname: Montastruc
– volume: 18
  start-page: 338
  year: 1995
  ident: ref_37
  article-title: Pramipexole in patients with early Parkinson’s disease
  publication-title: Clin. Neuropharmacol.
  doi: 10.1097/00002826-199508000-00006
  contributor:
    fullname: Hubble
– volume: 21
  start-page: 500
  year: 2006
  ident: ref_47
  article-title: The Parkinson-control study: A 1-year randomize, double-blind trial comapring piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson’s disease
  publication-title: Mov. Disord.
  doi: 10.1002/mds.20750
  contributor:
    fullname: Delwaide
– volume: 67
  start-page: 1225
  year: 2006
  ident: ref_42
  article-title: Dopamine agonists and cardiac valvulopathy in Parkinson disease: A case-control study
  publication-title: Neurology
  doi: 10.1212/01.wnl.0000238508.68593.1d
  contributor:
    fullname: Yamamoto
– volume: 57
  start-page: 701
  year: 2005
  ident: ref_17
  article-title: Short review on dopamine agonists: Insight into clinical and research studies relevant to Parkinson’s disease
  publication-title: Pharmacol. Rep.
  contributor:
    fullname: Radad
– volume: 15
  start-page: 287
  year: 2009
  ident: ref_100
  article-title: Dopamine agonists in the treatment of early Parkinson’s disease: A meta-analysis
  publication-title: Park. Relat. Disord.
  doi: 10.1016/j.parkreldis.2008.07.004
  contributor:
    fullname: Baker
– volume: 12
  start-page: 747
  year: 2013
  ident: ref_64
  article-title: Pramipexole in patients with early Parkinson’s disease (PROUD): A randomised delayed-start trial
  publication-title: Lancet Neurol.
  doi: 10.1016/S1474-4422(13)70117-0
  contributor:
    fullname: Schapira
– volume: 17
  start-page: 749
  year: 2018
  ident: ref_50
  article-title: Apomorphine subcutaneous infusion in patients with Parkinson’s disease with persistent motor fluctuations (TOLEDO): A multicentre, double-blind, randomised, placebo-controlled trial
  publication-title: Lancet Neurol.
  doi: 10.1016/S1474-4422(18)30239-4
  contributor:
    fullname: Katzenschlager
– volume: 3
  start-page: 31
  year: 2013
  ident: ref_48
  article-title: Inhaled apomorphine in patients with ‘on-off’ fluctuations: A randomized, double-blind, placebo-controlled, clinic and home based, parallel-group study
  publication-title: J. Park. Dis.
  contributor:
    fullname: Grosset
– volume: 63
  start-page: 584
  year: 1997
  ident: ref_79
  article-title: Prevalence of orthostatic hypotension in Parkinson’s disease
  publication-title: J. Neurol. Neurosurg. Psychiatry
  doi: 10.1136/jnnp.63.5.584
  contributor:
    fullname: Senard
– volume: 2000
  start-page: CD002259
  year: 2000
  ident: ref_101
  article-title: Pramipexole versus bromocriptine for levodopa-induced complications in Parkinson’s disease
  publication-title: Cochrane Database Syst. Rev.
  contributor:
    fullname: Clarke
– volume: 68
  start-page: 1108
  year: 2007
  ident: ref_58
  article-title: Ropinirole 24-hour prolonged release: Randomized, controlled study in advanced Parkinson disease
  publication-title: Neurology
  doi: 10.1212/01.wnl.0000258660.74391.c1
  contributor:
    fullname: Pahwa
– volume: 68
  start-page: 83
  year: 2012
  ident: ref_75
  article-title: Dopamine agonists and ischemic complications in Parkinson’s disease: A nested case-control study
  publication-title: Eur. J. Clin. Pharmacol.
  doi: 10.1007/s00228-011-1084-6
  contributor:
    fullname: Arbouw
– volume: 20
  start-page: 1388
  year: 2014
  ident: ref_54
  article-title: Rotigotine vs ropinirole in advanced stage Parkinson’s disease: Adouble-blind study
  publication-title: Park. Relat. Disord.
  doi: 10.1016/j.parkreldis.2014.10.005
  contributor:
    fullname: Mizuno
– volume: 94
  start-page: 749
  year: 2011
  ident: ref_2
  article-title: A systematic review of the worldwide prevalence and incidence of Parkinson’s disease
  publication-title: J. Med. Assoc. Thai
  contributor:
    fullname: Muangpaisan
– ident: ref_27
– volume: 18
  start-page: 501
  year: 2012
  ident: ref_84
  article-title: Factors related to orthostatic hypotension in Parkinson’s disease
  publication-title: Park. Relat. Disord.
  doi: 10.1016/j.parkreldis.2012.01.012
  contributor:
    fullname: Rey
– volume: 18
  start-page: 28
  year: 2009
  ident: ref_77
  article-title: Dopamine and angiotensin as renal counterregulatory systems controlling sodium balance
  publication-title: Curr. Opin. Nephrol. Hypertens.
  doi: 10.1097/MNH.0b013e32831a9e0b
  contributor:
    fullname: Gildea
– volume: 109
  start-page: 273
  year: 2008
  ident: ref_44
  article-title: Side effects of ropinirole in patients with idiopathic Parkinson’s disease
  publication-title: Bratisl. Lek. Listy
  contributor:
    fullname: Titlic
– volume: 13
  start-page: 351
  year: 2014
  ident: ref_10
  article-title: Risk of heart failure following treatment with dopamine agonists in Parkinson’s disease patients
  publication-title: Expert Opin. Drug Saf.
  doi: 10.1517/14740338.2014.888057
  contributor:
    fullname: Rey
– volume: 336
  start-page: 1106
  year: 2008
  ident: ref_32
  article-title: Grading quality of evidence and strength of recommendations for diagnostic tests and strategies
  publication-title: BMJ
  doi: 10.1136/bmj.39500.677199.AE
  contributor:
    fullname: Schunemann
– volume: 75
  start-page: 637
  year: 2004
  ident: ref_4
  article-title: Are men at greater risk for Parkinson’s disease than women?
  publication-title: J. Neurol. Neurosurg. Psychiatry
  doi: 10.1136/jnnp.2003.020982
  contributor:
    fullname: Wooten
– volume: 302
  start-page: F742
  year: 2012
  ident: ref_78
  article-title: Intrarenal dopamine modulates progressive angiotensin II-mediated renal injury
  publication-title: Am. J. Physiol. Ren. Physiol.
  doi: 10.1152/ajprenal.00583.2011
  contributor:
    fullname: Yang
– volume: 21
  start-page: 1094
  year: 2014
  ident: ref_105
  article-title: Meta-analysis of the efficacy and safety of long-acting non-ergot dopamine agonists in Parkinson’s disease
  publication-title: J. Clin. Neurosci.
  doi: 10.1016/j.jocn.2013.10.041
  contributor:
    fullname: Zhou
– volume: 23
  start-page: 935
  year: 2008
  ident: ref_43
  article-title: The frequency of cardiac valvular regurgitation in Parkinson’s disease
  publication-title: Mov. Disord.
  doi: 10.1002/mds.22036
  contributor:
    fullname: Yamashiro
– volume: 18
  start-page: 418
  year: 2003
  ident: ref_72
  article-title: Efficacy of piribedil as early combination to levodopa in patients with stable parkinson’s disease: A 6-month, randomized, placebo-controlled study
  publication-title: Mov. Disord.
  doi: 10.1002/mds.10359
  contributor:
    fullname: Ziegler
– volume: 247
  start-page: 868
  year: 2000
  ident: ref_85
  article-title: Levodopa, bromocriptine and selegiline modify cardiovascular responses in Parkinson’s disease
  publication-title: J. Neurol.
  doi: 10.1007/s004150070075
  contributor:
    fullname: Haapaniemi
– ident: ref_28
– ident: ref_30
– volume: 60
  start-page: 1721
  year: 2003
  ident: ref_46
  article-title: A Controlled Trial of Rotigotine Monotherapy in Early Parkinson’s Disease
  publication-title: Arch. Neurol.
  doi: 10.1001/archneur.60.12.1721
  contributor:
    fullname: Blindeauer
– volume: 6
  start-page: 826
  year: 2007
  ident: ref_74
  article-title: Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson’s disease
  publication-title: Lancet Neurol.
  doi: 10.1016/S1474-4422(07)70218-1
  contributor:
    fullname: Antonini
– ident: ref_3
– volume: 19
  start-page: 508
  year: 1992
  ident: ref_83
  article-title: Orthostatic hypotension in older adults. The Cardiovascular Health Study. CHS Collaborative Research Group
  publication-title: Hypertension
  doi: 10.1161/01.HYP.19.6.508
  contributor:
    fullname: Rutan
– volume: 64
  start-page: 380
  year: 2011
  ident: ref_31
  article-title: GRADE guidelines: A new series of articles in the Journal of Clinical Epidemiology
  publication-title: J. Clin. Epidemiol.
  doi: 10.1016/j.jclinepi.2010.09.011
  contributor:
    fullname: Guyatt
– volume: 3
  start-page: 257
  year: 2016
  ident: ref_34
  article-title: Associations Between Cardiovascular Events and Nonergot Dopamine Agonists in Parkinson’s Disease
  publication-title: Mov. Disord. Clin. Pract.
  doi: 10.1002/mdc3.12286
  contributor:
    fullname: Crispo
– volume: 2016
  start-page: 8298503
  year: 2016
  ident: ref_65
  article-title: Ophthalmologic baseline characteristics and 2-year ophthalmologic safety profile of pramipexole IR compared with ropinirole IR in patients with early Parkinson’s disease
  publication-title: Park. Dis.
  contributor:
    fullname: Seiple
– volume: 116
  start-page: 179
  year: 2009
  ident: ref_22
  article-title: Risk of valvular heart disease associated with the use of dopamine agonists in Parkinson’s disease: A systematic review
  publication-title: J. Neural Transm.
  doi: 10.1007/s00702-008-0179-4
  contributor:
    fullname: Steiger
– volume: 39
  start-page: S1
  year: 2012
  ident: ref_7
  article-title: Canadian Guidelines on Parkinson’s Disease
  publication-title: Can. J. Neurol. Sci.
  doi: 10.1017/S031716710001516X
  contributor:
    fullname: Grimes
– volume: 19
  start-page: 11
  year: 1998
  ident: ref_89
  article-title: Safety of selegiline (deprenyl) in the treatment of Parkinson’s disease
  publication-title: Drug Saf.
  doi: 10.2165/00002018-199819010-00002
  contributor:
    fullname: Heinonen
– volume: 30
  start-page: 739
  year: 2013
  ident: ref_76
  article-title: Risk of heart failure associated with dopamine agonists: A nested case-control study
  publication-title: Drugs Aging
  doi: 10.1007/s40266-013-0102-z
  contributor:
    fullname: Hsieh
– volume: 18
  start-page: 8
  year: 2008
  ident: ref_81
  article-title: Prevalence of orthostatic hypotension
  publication-title: Clin. Auton. Res.
  doi: 10.1007/s10286-007-1001-3
  contributor:
    fullname: Low
– volume: 57
  start-page: 1461
  year: 2000
  ident: ref_86
  article-title: Acute orthostatic hypotension when starting dopamine agonists in Parkinson’s disease
  publication-title: Arch. Neurol.
  doi: 10.1001/archneur.57.10.1461
  contributor:
    fullname: Kujawa
– volume: 27
  start-page: 259
  year: 2013
  ident: ref_11
  article-title: Management of motor and non-motor symptoms in Parkinson’s disease
  publication-title: CNS Drugs
  doi: 10.1007/s40263-013-0053-2
  contributor:
    fullname: Sprenger
– volume: 339
  start-page: 1044
  year: 1998
  ident: ref_1
  article-title: Parkinson’s disease. First of two parts
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJM199810083391506
  contributor:
    fullname: Lang
– volume: 61
  start-page: 1044
  year: 2004
  ident: ref_49
  article-title: Pramipexole vs levodopa as initial treatment for Parkinson disease: A 4-year randomized controlled trial
  publication-title: Arch. Neurol.
  contributor:
    fullname: Holloway
– volume: 77
  start-page: 767
  year: 2011
  ident: ref_63
  article-title: Extended-release pramipexole in advanced Parkinson disease: A randomized controlled trial
  publication-title: Neurology
  doi: 10.1212/WNL.0b013e31822affdb
  contributor:
    fullname: Schapira
– volume: 77
  start-page: 1280
  year: 2002
  ident: ref_97
  article-title: Valvular heart disease in patients taking pergolide
  publication-title: Mayo Clin. Proc.
  doi: 10.4065/77.12.1280
  contributor:
    fullname: Pritchett
– volume: 15
  start-page: 15
  year: 2008
  ident: ref_16
  article-title: Clinical risk-benefit assessment of dopamine agonists
  publication-title: Eur. J. Neurol.
  doi: 10.1111/j.1468-1331.2008.02214.x
  contributor:
    fullname: Moller
– volume: 21
  start-page: 34
  year: 2012
  ident: ref_21
  article-title: Dopamine agonist use and the risk of heart failure
  publication-title: Pharmacoepidemiol. Drug Saf.
  doi: 10.1002/pds.2267
  contributor:
    fullname: Renoux
– volume: 13
  start-page: 39
  year: 1998
  ident: ref_39
  article-title: Ropinirole in the treatment of early Parkinson’s disease: A 6-month interim report of a 5-year levodopa-controlled study
  publication-title: Mov. Disord.
  doi: 10.1002/mds.870130111
  contributor:
    fullname: Rascol
– volume: 69
  start-page: 187
  year: 2007
  ident: ref_96
  article-title: Risk factors for somnolence, edema, and hallucinations in early Parkinson disease
  publication-title: Neurology
  doi: 10.1212/01.wnl.0000265593.34438.00
  contributor:
    fullname: Biglan
– volume: 33
  start-page: 147
  year: 2010
  ident: ref_103
  article-title: Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson’s disease: Meta-analysis of randomized controlled trials
  publication-title: Drug Saf.
  doi: 10.2165/11319860-000000000-00000
  contributor:
    fullname: Kulisevsky
– volume: 97
  start-page: e11316
  year: 2018
  ident: ref_106
  article-title: Meta-analysis of the adverse events associated with extended-release versus standard immediate-release pramipexole in Parkinson disease
  publication-title: Medicine
  doi: 10.1097/MD.0000000000011316
  contributor:
    fullname: Shen
– volume: 65
  start-page: 358
  year: 2012
  ident: ref_24
  article-title: The risk of new onset heart failure associated with dopamine agonist use in Parkinson’s disease
  publication-title: Pharmacol. Res.
  doi: 10.1016/j.phrs.2011.11.009
  contributor:
    fullname: Mokhles
– volume: 22
  start-page: 1936
  year: 2007
  ident: ref_107
  article-title: Meta-analysis of heart valve abnormalities in Parkinson’s disease patients treated with dopamine agonists
  publication-title: Mov. Disord.
  doi: 10.1002/mds.21639
  contributor:
    fullname: Simonis
– volume: 8
  start-page: 929
  year: 2009
  ident: ref_73
  article-title: A reassessment of risks and benefits of dopamine agonists in Parkinson’s disease
  publication-title: Lancet Neurol.
  doi: 10.1016/S1474-4422(09)70225-X
  contributor:
    fullname: Antonini
– volume: 35
  start-page: 174
  year: 2012
  ident: ref_53
  article-title: Efficacy and safety of extended-versus immediate-release pramipexole in Japanese patients with advanced and L-dopa-undertreated Parkinson disease: A double-blind, randomized trial
  publication-title: Clin. Neuropharmacol.
  doi: 10.1097/WNF.0b013e31825f77b9
  contributor:
    fullname: Mizuno
– volume: 2008
  start-page: CD006564
  year: 2008
  ident: ref_104
  article-title: Dopamine agonist therapy in early Parkinson’s disease
  publication-title: Cochrane Database Syst. Rev.
  contributor:
    fullname: Stowe
– volume: 49
  start-page: 1060
  year: 1997
  ident: ref_36
  article-title: Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson’s disease
  publication-title: Neurology
  doi: 10.1212/WNL.49.4.1060
  contributor:
    fullname: Guttman
– volume: 26
  start-page: 1464
  year: 2011
  ident: ref_62
  article-title: Pardoprunox in early Parkinson’s disease: Results from 2 large, randomized double-blind trials
  publication-title: Mov. Disord.
  doi: 10.1002/mds.23590
  contributor:
    fullname: Sampaio
– volume: 22
  start-page: 234
  year: 2007
  ident: ref_20
  article-title: Valvular heart disease in Parkinson’s disease patients treated with dopamine agonists: A reader-blinded monocenter echocardiography study
  publication-title: Mov. Disord.
  doi: 10.1002/mds.21225
  contributor:
    fullname: Junghanns
– volume: 2001
  start-page: CD001516
  year: 2001
  ident: ref_102
  article-title: Ropinirole for levodopa-induced complications in Parkinson’s disease
  publication-title: Cochrane Database Syst. Rev.
  contributor:
    fullname: Clarke
– volume: 6
  start-page: 401
  year: 2016
  ident: ref_108
  article-title: Rotigotine in Combination with the MAO-B Inhibitor Selegiline in Early Parkinson’s Disease: A Post Hoc Analysis
  publication-title: J. Park. Dis.
  contributor:
    fullname: Giladi
– ident: ref_26
– volume: 7
  start-page: 61
  year: 2017
  ident: ref_70
  article-title: A randomized, fixed-dose, dose-response study of ropinirole prolonged release in advanced Parkinson’s disease
  publication-title: Neurodegener. Dis. Manag.
  doi: 10.2217/nmt-2016-0038
  contributor:
    fullname: Zesiewicz
– volume: 68
  start-page: 272
  year: 2007
  ident: ref_69
  article-title: Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease
  publication-title: Neurology
  doi: 10.1212/01.wnl.0000252355.79284.22
  contributor:
    fullname: Watts
– volume: 24
  start-page: 941
  year: 2010
  ident: ref_18
  article-title: Dopamine Receptor Agonists for the Treatment of Early or Advanced Parkinson’s Disease
  publication-title: CNS Drugs
  doi: 10.2165/11537810-000000000-00000
  contributor:
    fullname: Rascol
– volume: 56
  start-page: M749
  year: 2001
  ident: ref_87
  article-title: Effect of levodopa on orthostatic and postprandial hypotension in elderly Parkinsonian patients
  publication-title: J. Gerontol. A Biol. Sci. Med. Sci.
  doi: 10.1093/gerona/56.12.M749
  contributor:
    fullname: Boerman
– volume: 35
  start-page: 173
  year: 2008
  ident: ref_23
  article-title: Pergolide associated cardiac valvulopathy based on Ontario administrative data
  publication-title: Can. J. Neurol. Sci.
  doi: 10.1017/S0317167100008593
  contributor:
    fullname: Zadikoff
– volume: 3
  start-page: 11
  year: 2014
  ident: ref_68
  article-title: The efficacy and safety of pramipexole ER versus IR in Chinese patients with Parkinson’s disease: A randomized, double-blind, double-dummy, parallel-group study
  publication-title: Transl. Neurodegener.
  doi: 10.1186/2047-9158-3-11
  contributor:
    fullname: Wang
– volume: 250
  start-page: 90
  year: 2003
  ident: ref_35
  article-title: Ropinirole as an adjunct to levodopa in the treatment of Parkinson’s disease: A 16-week bromocriptine controlled study
  publication-title: J. Neurol.
  doi: 10.1007/s00415-003-0937-z
  contributor:
    fullname: Im
– volume: 49
  start-page: 162
  year: 1997
  ident: ref_38
  article-title: Clinical evaluation of pramipexole in advanced Parkinson’s disease: Results of a double-blind, placebo-controlled, parallel-group study
  publication-title: Neurology
  doi: 10.1212/WNL.49.1.162
  contributor:
    fullname: Lieberman
– volume: 29
  start-page: 23
  year: 2013
  ident: ref_67
  article-title: Evaluation of the safety and tolerability of rasagiline in the treatment of the early stages of Parkinson’s disease
  publication-title: Curr. Med. Res. Opin.
  doi: 10.1185/03007995.2012.752351
  contributor:
    fullname: Viallet
– volume: 18
  start-page: 1324
  year: 2003
  ident: ref_56
  article-title: Randomized, double-blind, 3-month parallel study of the effects of pramipexole, pergolide, and placebo on Parkinsonian tremor
  publication-title: Mov. Disord.
  doi: 10.1002/mds.10538
  contributor:
    fullname: Navan
– volume: 30
  start-page: 587
  year: 2013
  ident: ref_14
  article-title: Dopamine Agonist Withdrawal Syndrome: Implications for Patient Care
  publication-title: Drugs Aging
  doi: 10.1007/s40266-013-0090-z
  contributor:
    fullname: Nirenberg
– volume: 27
  start-page: 81
  year: 2013
  ident: ref_95
  article-title: Rotigotine transdermal patch for the treatment of Parkinson’s Disease
  publication-title: Fundam. Clin. Pharmacol.
  doi: 10.1111/j.1472-8206.2012.01028.x
  contributor:
    fullname: Rey
– volume: 80
  start-page: 578
  year: 2002
  ident: ref_91
  article-title: Functional and autoradiographic characterization of dopamine D2-like receptors in the guinea pig heart
  publication-title: Can. J. Physiol. Pharmacol.
  doi: 10.1139/y02-081
  contributor:
    fullname: Rousseau
– volume: 46
  start-page: 1333
  year: 2005
  ident: ref_88
  article-title: Neurocirculatory abnormalities in Parkinson disease with orthostatic hypotension: Independence from levodopa treatment
  publication-title: Hypertension
  doi: 10.1161/01.HYP.0000188052.69549.e4
  contributor:
    fullname: Goldstein
– volume: 120
  start-page: 347
  year: 2013
  ident: ref_9
  article-title: Is there room for non-dopaminergic treatment in Parkinson disease?
  publication-title: J. Neural Transm.
  doi: 10.1007/s00702-012-0946-0
  contributor:
    fullname: Lieberman
– volume: 26
  start-page: 1259
  year: 2011
  ident: ref_66
  article-title: PREPARED: Comparison of prolonged and immediate release ropinirole in advanced Parkinson’s disease
  publication-title: Mov. Disord.
  doi: 10.1002/mds.23498
  contributor:
    fullname: Stocchi
– volume: 19
  start-page: 1022
  year: 2013
  ident: ref_71
  article-title: The efficacy and safety of ropinirole prolonged release tablets as adjunctive therapy in Chinese subjects with advanced Parkinson’s disease: A multicenter, double-blind, randomized, placebo-controlled study
  publication-title: Park. Relat. Disord.
  doi: 10.1016/j.parkreldis.2013.07.009
  contributor:
    fullname: Zhang
– volume: 4
  start-page: 361
  year: 2014
  ident: ref_57
  article-title: A randomized study of rotigotine dose response on ‘off’ time in advanced Parkinson’s disease
  publication-title: J. Park. Dis.
  contributor:
    fullname: Nicholas
– volume: 342
  start-page: 1484
  year: 2000
  ident: ref_60
  article-title: A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJM200005183422004
  contributor:
    fullname: Rascol
– volume: 17
  start-page: 724
  year: 2011
  ident: ref_80
  article-title: Prevalence of orthostatic hypotension in Parkinson’s disease: A systematic review and meta-analysis
  publication-title: Park. Relat. Disord.
  doi: 10.1016/j.parkreldis.2011.04.016
  contributor:
    fullname: Velseboer
– volume: 5
  start-page: 235
  year: 1998
  ident: ref_41
  article-title: A double-blind, placebo-controlled, randomized, multi-center study of pramipexole in advanced Parkinson’s disease
  publication-title: Eur. J. Neurol.
  doi: 10.1046/j.1468-1331.1998.530235.x
  contributor:
    fullname: Wermuth
– volume: 84
  start-page: 133
  year: 1999
  ident: ref_90
  article-title: Dopamine receptors--physiological understanding to therapeutic intervention potential
  publication-title: Pharmacol. Ther.
  doi: 10.1016/S0163-7258(99)00029-7
  contributor:
    fullname: Emilien
– volume: 112
  start-page: 583
  year: 2007
  ident: ref_92
  article-title: The dopaminergic system in hypertension
  publication-title: Clin. Sci.
  doi: 10.1042/CS20070018
  contributor:
    fullname: Zeng
– volume: 34
  start-page: 143
  year: 2010
  ident: ref_5
  article-title: Geographic and ethnic variation in Parkinson disease: A population-based study of US Medicare beneficiaries
  publication-title: Neuroepidemiology
  doi: 10.1159/000275491
  contributor:
    fullname: Evanoff
– volume: 26
  start-page: 37
  year: 2011
  ident: ref_51
  article-title: Twice-daily, low-dose pramipexole in early Parkinson’s disease: A randomized, placebo-controlled trial
  publication-title: Mov. Disord.
  doi: 10.1002/mds.23396
  contributor:
    fullname: Kieburtz
– volume: 20
  start-page: 364
  year: 2008
  ident: ref_8
  article-title: Cognitive and behavioural impairment in Parkinson’s disease
  publication-title: Int. Rev. Psychiatry
  doi: 10.1080/09540260802095123
  contributor:
    fullname: Merims
– volume: 29
  start-page: 985
  year: 2015
  ident: ref_99
  article-title: Risks of Cardiac Valve Regurgitation and Heart Failure Associated with Ergot- and Non-Ergot-Derived Dopamine Agonist Use in Patients with Parkinson’s Disease: A Systematic Review of Observational Studies
  publication-title: CNS Drugs
  doi: 10.1007/s40263-015-0293-4
  contributor:
    fullname: Tran
– volume: 89
  start-page: 279
  year: 2012
  ident: ref_15
  article-title: Anti-Parkinson drugs and orexin neurons
  publication-title: Vitam. Horm.
  doi: 10.1016/B978-0-12-394623-2.00015-9
  contributor:
    fullname: Katsuki
– volume: 6
  start-page: 513
  year: 2007
  ident: ref_59
  article-title: Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson’s disease: A double-blind, double-dummy, randomised controlled trial
  publication-title: Lancet Neurol.
  doi: 10.1016/S1474-4422(07)70108-4
  contributor:
    fullname: Poewe
– volume: 6
  start-page: 168
  year: 2013
  ident: ref_13
  article-title: Hyperprolactinemia
  publication-title: J. Hum. Reprod. Sci.
  doi: 10.4103/0974-1208.121400
  contributor:
    fullname: Majumdar
– volume: 15
  start-page: S44
  year: 2009
  ident: ref_12
  article-title: Role of dopamine receptor agonists in the treatment of early Parkinson’s disease
  publication-title: Park. Relat. Disord.
  doi: 10.1016/S1353-8020(09)70835-1
  contributor:
    fullname: Bonuccelli
– volume: 21
  start-page: 2110
  year: 2006
  ident: ref_61
  article-title: Early piribedil monotherapy of parkinson’s disease: A planned seven-month report of the REGAIN study
  publication-title: Mov. Disord.
  doi: 10.1002/mds.21122
  contributor:
    fullname: Rascol
– volume: 9
  start-page: 573
  year: 2010
  ident: ref_45
  article-title: Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: A randomised, double-blind, placebo-controlled trial
  publication-title: Lancet Neurol.
  doi: 10.1016/S1474-4422(10)70106-X
  contributor:
    fullname: Barone
– volume: 68
  start-page: 1262
  year: 2007
  ident: ref_52
  article-title: Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study
  publication-title: Neurology
  doi: 10.1212/01.wnl.0000259516.61938.bb
  contributor:
    fullname: LeWitt
– ident: ref_29
– volume: 18
  start-page: S80
  year: 2012
  ident: ref_19
  article-title: Impulse control disorders in Parkinson’s disease
  publication-title: Park. Relat. Disord.
  doi: 10.1016/S1353-8020(11)70026-8
  contributor:
    fullname: Vilas
– volume: 21
  start-page: 1109
  year: 2006
  ident: ref_25
  article-title: Valvular heart disease in Parkinson’s disease vs. controls: An echocardiographic study
  publication-title: Mov. Disord.
  doi: 10.1002/mds.20887
  contributor:
    fullname: Peralta
– volume: 20
  start-page: 602
  year: 2005
  ident: ref_55
  article-title: Long-term efficacy and safety of pramipexole in advanced Parkinson’s disease: Results from a European multicenter trial
  publication-title: Mov. Disord.
  doi: 10.1002/mds.20397
  contributor:
    fullname: Moller
– volume: 53
  start-page: 364
  year: 1999
  ident: ref_33
  article-title: A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson’s disease. The 053 Study Group
  publication-title: Neurology
  doi: 10.1212/WNL.53.2.364
  contributor:
    fullname: Korczyn
– volume: 19
  start-page: 234
  year: 1996
  ident: ref_40
  article-title: Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson’s disease
  publication-title: Clin. Neuropharmacol.
  doi: 10.1097/00002826-199619030-00005
  contributor:
    fullname: Rascol
– volume: 30
  start-page: 173
  year: 2005
  ident: ref_82
  article-title: High prevalence of orthostatic hypotension and its correlation with potentially causative medications among elderly veterans
  publication-title: J. Clin. Pharm. Ther.
  doi: 10.1111/j.1365-2710.2005.00629.x
  contributor:
    fullname: Poon
– volume: 374
  start-page: 577
  year: 2009
  ident: ref_98
  article-title: Drug-induced fibrotic valvular heart disease
  publication-title: Lancet
  doi: 10.1016/S0140-6736(09)60252-X
  contributor:
    fullname: Bhattacharyya
SSID ssj0000800350
Score 2.3149438
SecondaryResourceType review_article
Snippet Reports suggest possible risks of adverse cardiovascular reactions, including heart failure, associated with non-ergot dopamine agonist (DA) use in Parkinson's...
Reports suggest possible risks of adverse cardiovascular reactions, including heart failure, associated with non-ergot dopamine agonist (DA) use in Parkinson’s...
SourceID doaj
pubmedcentral
proquest
gale
crossref
pubmed
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 776
SubjectTerms Agonists
Bias
Bromocriptine
Canada
Cardiac glycosides
Cardiac patients
Cardiotonic agents
Cardiovascular disease
Cardiovascular diseases
cardiovascular reactions
Clinical trials
Comparative analysis
Complications and side effects
Congestive heart failure
Diseases
Dopamine
Drug dosages
Edema
Enzymes
Ergot
Heart diseases
Heart failure
Intervention
medication safety
Movement disorders
Neurodegenerative diseases
non-ergot dopamine agonists
Online databases
Ontario
Orthostatic hypotension
Parkinson's disease
Phenols
Restless legs syndrome
Risk factors
Ropinirole
Systematic Review
SummonAdditionalLinks – databaseName: Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQT1wQUB6BgoyEQByiJn4k9nFpu1ohUaSKSr1FfsRlQXVQkx56qMTf4O_xS5hx0tUGDly4rp1V4pnxfGPPfEPI6wJ2PB98lTulJAQozuZaS5bDbilcDRBWpm4NH4-r1an4cCbPtlp9YU7YSA88Lty-tEpCsKQDE15Y4fCeS3ouuArgrafdt2BbwdTXCQdxWYz3khzi-n2LHRfAq0BAoZDCZuaHEl3_35vylleaZ0xuuaDlfXJvwo50Mb7zA3KnjQ_J7iJC3HxxTd_QlM2Zjsl3yc1xF_Ojy_NuoIcQF18AmKSL8w55cntqoqcA_OjJuv9Gu0BXoO4DXZo15qin0U-IC2nq1ty39GCWtEpP2rEaoqfrSLFsOlWQ_frxs6eH433PI3K6PPp8sMqnVgu5Azw05FJ4y6QqlLeFBydfSuelqyvpHDO1Lh14dWc4r60JNlinrAtetLW2QWgTSv6Y7MQutk8J5YUxLIDonbHC2KAqQI1g3MpWmjmnM_LuduGb7yOjRgORCAqp-VNIGXmPktnMQy7s9ANoSDNpSPMvDcnIW5RrgxYLwnNmKjyA10Xuq2aBfEBcMFZmZG82EyzNzYdvNaOZLL1veCqEgbiwyMirzTA-idlrse2u0hyNZ20C_uLJqEibT-Ia2ZlreFrNVGz2zfORuP6SeMDLEtAz5-Wz_7FKz8ldBnhtPLbeIzvD5VX7AvDWYF8m0_oNez4o-w
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9NAEF5BeuGCgPIILWiREIiDVXsf9vqE0jZRhERAEZV6s_bhTSNUu8TuoQck_gZ_j1_CzNoJNUhcvWvL9ry-mZ0HIa9j0HjOuzSySklwUKyJ8lyyCLSlsBlAWBmmNXxcpPMz8eFcnvcBt6ZPq9zqxKCoXW0xRn7EQ8EB4O_4_dW3CKdG4elqP0LjLtljCVdqRPaOp4vPy12UBfEQl3F3PsnBvz8yOHkBrAs4Fgpb2QzsUWjb_69yvmWdhpmTt0zR7AG532NIOumI_pDcKatHZH9Sgf98eUPf0JDVGcLl--T7oq6i6WZVt_QU_ONLAJV0sqqxX25DdeUoAEC6XDdfae3pHNi-pTO9xlz1sPoJ8SENU5ubkp4MklfpsuyqIhq6riiWT4dKsl8_fjb0tDv3eUzOZtMvJ_OoH7kQWcBFbSSFM0yqWDkTOzD2ibRO2iyV1jKd5YkF624155nR3nhjlbHeiTLLjRe59gl_QkZVXZXPCOWx1swDC1hthDZepYAeQciVSXNmbT4m77Y_vrjqOmsU4JEgkYq_iTQmx0iZ3T7siR0u1JtV0YtYIY2S4FbnngknjLB4IiodF1x5wHUpG5O3SNcCJReIZ3VfgACviz2wign2BeKCsWRMDgc7QeLscHnLGUUv8U3xhz_H5NVuGe_ELLaqrK_DnhxjbgIe8bRjpN0n8Ry7NGdwtxqw2OCbhyvV-iL0A08SQNGcJ8___14H5B4DRNYFpg_JqN1cly8AUbXmZS82vwEDzCOf
  priority: 102
  providerName: ProQuest
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV3db9MwELdgSGgvEzA-AgMZCTHxEEj8kdoPCJVtVYW0IU1U2ltkO3FXYMloMomJf547Jy0NjNfasZrcne_3s--DkFcJ7HiFL7LYKSWBoDgbay1ZDLulcCOAsDJ0azg-yaYz8elMnv1Jj-4_YHMjtcN-UrPl97c_f1x_AIN_j4wTKPs7i80UwGEAV1BYneY2ucPAL2KA13EP9r_22IiHlq0MyHvMQVu7e8sbF9kmd7nGwrnYxnjDZYXK_v_u3xsObBhcueGtJvfITg8z6bjTi_vkVlk9ILvjCij2xTV9TUPgZzhR3yW_TuoqPlrO65YeAoW-ANxJx_MaS-o21FQFBYxITxfNN1p7OgXLaOnELDCcPYx-RghJQ2PnpqQHg_hWelp2iRMNXVQUM6xDstl-Qw-7i6GHZDY5-nIwjfueDLED4NTGUhSWSZWowiYFoIFUukK6USadY2akUwfu3xnOR9Z4661T1vlClCNtvdDGp_wR2arqqnxCKE-MYR50xBkrjPUqA3gJu4CymWbO6Yi8WX32_LIrvZEDZUFp5X9LKyIfUS7reVg0O_xQL-d5b4O5tEoC79aeiUJY4fDKVBZccOUB-GUsIvso1RyVDUTnTJ-hAH8Xi2TlYywcBGrD0ojsDWaCSbrh8Eov8pVG5zxkzACBTCLycj2MT2KYW1XWV2GOxkM5AUs87tRo_UorbYyIGijY4J2HI9XiPBQMT1OA2ZynT_-76DOyzQCtdYfWe2SrXV6VzwFttfZFMKLfLesmaQ
  priority: 102
  providerName: Scholars Portal
Title Non-Ergot Dopamine Agonists and the Risk of Heart Failure and Other Adverse Cardiovascular Reactions in Parkinson's Disease
URI https://www.ncbi.nlm.nih.gov/pubmed/39199470
https://www.proquest.com/docview/3097838620
https://www.proquest.com/docview/3099142241
https://pubmed.ncbi.nlm.nih.gov/PMC11352331
https://doaj.org/article/5b855239f24d4b4c81665d3438f25662
Volume 14
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NjtMwELZ2lwsXBCw_gaUyEgJxyDaJ7cQ5drutKqSWVcVKe4tsJy4B6qya7IEDEq_B6_EkjJ2kauDGJYfYjpLMjOcbe-YzQm8CmPFynce-4pxBgKKkn6Ys8mG2pCoBCMvcaQ3LVby4ph9u2M0RivtaGJe0r2R5br5tz0352eVW3m7VuM8TG18tp2EIsIGQcHyMjsH_HsToXzoMRFjQ7kkSiOnH0p62AB4Fgglu6WsGPshR9f87IR94pGG25IH7mT9EDzrciCft-z1CR4V5jE4nBmLm7Xf8FrtMTrdEfop-rCrjz3abqsGXEBNvAUjiyaayHLk1FibHAPrwuqy_4krjBah6g-eitPnprvWjxYTYndRcF3g6SFjF66KthKhxabAtmXbVY79__qrxZbvX8wRdz2efpgu_O2bBV4CFGp_RXEaMBzyXQQ4OPmQqZyqJmVKRSNJQgUdXgpBECi21VFwqndMiSaWmqdAheYpOTGWK5wiTQIhIg9iVkFRIzWNAjGDYXMZppFTqoff9j89uWzaNDKIQK6TsbyF56MJKZt_P8mC7G9Vuk3XakDHJGahCqiOaU0mV3QVlOaGEa8ByceShd1aumbVWEJ4SXdEBvK7lvcomlguI0CgKPXQ26AlWpobNvWZknZXXGXFFMBATBh56vW-2I23mmimqO9cntetsFB7xrFWk_SeR1DIzJzCaD1Rs8M3DFjAJxwHem8CL_x_6Et2PAKG1C9Vn6KTZ3RWvAGE1coTuXcxWV-uRW6GA65LykTOyP-wTLSY
link.rule.ids 230,314,727,780,784,864,885,2102,2221,21388,24318,27924,27925,33744,33745,43805,53791,53793,74302
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9NAEF5BeoALAgrUtMAiIRAHq_Y-_DihtE0UoA0oaqXerH14Q4Rqt3F64IDE3-Dv8UuYWTuhBomrd23Zntc3s_Mg5FUEGs86m4QmyyQ4KEaHeS5ZCNpSmBQgrPTTGk6myeRMfDiX513ArenSKtc60StqWxuMke9zX3AA-Dt6d3kV4tQoPF3tRmjcJlvYOV0OyNbBaPp5tomyIB7iMmrPJzn49_saJy-AdQHHIsNWNj175Nv2_6ucb1infubkDVM0vk_udRiSDluiPyC3yuoh2R5W4D9ffKOvqc_q9OHybfJ9WlfhaDmvV_QI_OMLAJV0OK-xX25DVWUpAEA6WzRfae3oBNh-RcdqgbnqfvUT4kPqpzY3JT3sJa_SWdlWRTR0UVEsn_aVZL9-_GzoUXvu84icjUenh5OwG7kQGsBFq1AKq5nMoszqyIKxj6Wx0qSJNIapNI8NWHejOE-1ctppk2njrCjTXDuRKxfzx2RQ1VW5QyiPlGIOWMAoLZR2WQLoEYQ800nOjMkD8nb944vLtrNGAR4JEqn4m0gBOUDKbPZhT2x_oV7Oi07ECqkzCW517piwQguDJ6LScmAMB7guYQF5g3QtUHKBeEZ1BQjwutgDqxhiXyAuGIsDstfbCRJn-strzig6iW-KP_wZkJebZbwTs9iqsr72e3KMuQl4xJOWkTafxHPs0pzC3VmPxXrf3F-pFl98P_A4BhTNefz0_-_1gtyZnJ4cF8fvpx93yV0G6KwNUu-RwWp5XT4DdLXSzzsR-g3H7SaH
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9NAEF5BKiEuCCjQQIFFQiAOVmzvrr0-obRJFF6hiqjUm7UPb4hQ7RK7Bw5I_A3-Hr-EmbUTapC4eteW7Xl9MzsPQp6HoPGss0lgpBTgoBgdZJmIA9CW3KQAYYWf1vBhkcxP-dszcdblP9VdWuVWJ3pFbSuDMfIR8wUHgL_DkevSIk4ms9cXXwOcIIUnrd04jetkD6xiGA_I3tF0cbLcRVwQGzERtmeVDHz9kcYpDGBpwMmQ2NamZ5t8C_9_FfUVS9XPorxilma3ya0OT9JxywB3yLWivEv2xyX40uff6AvqMzx96HyffF9UZTDdrKqGTsBXPgeAScerCnvn1lSVlgIYpMt1_YVWjs5BBBo6U2vMW_erHxErUj_BuS7ocS-RlS6LtkKipuuSYim1ryr79eNnTSftGdA9cjqbfjqeB934hcAARmoCwa2OhQyl1aEFwx8JY4VJE2FMrNIsMmDpjWIs1cppp43UxllepJl2PFMuYvfJoKzK4oBQFioVO2AHozRX2skEkCQIvNRJFhuTDcmr7Y_PL9ouGzl4J0ik_G8iDckRUma3D_tj-wvVZpV34pYLLQW42JmLueWaGzwdFZZxJh1gvCQekpdI1xylGIhnVFeMAK-L_bDyMfYIYjyOoyE57O0E6TP95S1n5J301_kfXh2SZ7tlvBMz2sqiuvR7Moy_cXjEg5aRdp_EMuzYnMLdssdivW_ur5Trz743eBQBomYsevj_93pKboD05O_fLN49IjdjAGptvPqQDJrNZfEYgFajn3QS9BthECq0
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Non-Ergot+Dopamine+Agonists+and+the+Risk+of+Heart+Failure+and+Other+Adverse+Cardiovascular+Reactions+in+Parkinson%27s+Disease&rft.jtitle=Brain+sciences&rft.au=Crispo%2C+James+A+G&rft.au=Farhat%2C+Nawal&rft.au=Fortin%2C+Yannick&rft.au=Perez-Lloret%2C+Santiago&rft.date=2024-07-31&rft.issn=2076-3425&rft.eissn=2076-3425&rft.volume=14&rft.issue=8&rft_id=info:doi/10.3390%2Fbrainsci14080776&rft_id=info%3Apmid%2F39199470&rft.externalDocID=39199470
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2076-3425&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2076-3425&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2076-3425&client=summon